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Abstract
Background: Multiple neuropeptides, sometimes with opposing functions, can be produced from one precursor
gene. To study the roles of the different neuropeptides encoded by one large precursor we developed a method
to overexpress minigenes and establish local secretion.
Results: We fused the signal peptide from the Von Willebrand Factor (VWF) to a furin site followed by a processed
form of the Agouti related protein (AgRP), AgRP83-132 or a-melanocyte stimulating hormone. In vitro, these
minigenes were secreted and biologically active. Additionally, the proteins of the minigenes were not transported
into projections of primary neurons, thereby ensuring local release. In vivo administration of VWF-AgRP83-132, using
an adeno-associated viral vector as a delivery vehicle, into the paraventricular hypothalamus increased body weight
and food intake of these rats compared to rats which received a control vector.
Conclusions: This study demonstrated that removal of the N-terminal part of full length AgRP and addition of a
VWF signal peptide is a successful strategy to deliver neuropeptide minigenes to the brain and establish local
neuropeptide secretion.
Background
Numerous neuropeptide precusors have been implicated
in the regulation of energy balance, such as pro-opiome-
lanocortin (POMC), melanin concentrating hormone
(MCH) and ghrelin. Neuropeptide precursors have a
propeptide which translocates the neuropeptide precur-
sors from the rough-endoplasmatic reticulum to the
trans-golgi network (TGN). From the TGN the peptide
precursors traffic into immature secretory vesicles where
they are cleaved once or multiple times by prohormone
convertases (PC) 1/3 and/or 2 to generate functional
neuropeptides [1-3]. Through budding and fusion the
immature vesicles become mature, dense, vesicles which
release their content upon a specific signal [4].
The processing of neuropeptide precursors results in
multiple biologically active peptides, sometimes with
opposing effects; an example is the POMC gene. Pre-
pro POMC is processed into several neuropeptides with
anorexigenic functions, e.g. a-melanocyte stimulating
hormone (MSH) and b-MSH, but also into an opioid
with “orexigenic” function, namely b-endorphin [5-9].
Loss of the whole POMC gene results in hyperphagia
and obesity [10]. Although there is strong evidence that
the lack of melanocortin signaling in POMC knockout
mice explains the phenotype, mice lacking only the
b-endorphin part of the POMC gene are also hyperpha-
gic and obese [11]. Another example of a precursor
gene that encodes for peptides with diverse effects is
pre-pro-ghrelin which encodes for ghrelin, an appetite
stimulating hormone, and obestatin, an appetite sup-
pressing hormone [12]. Therefore, it is important to
determine the role of individual neuropeptides encoded
by a precursor gene.
To investigate the role of specific neuropeptides,
synthesized neuropeptides can be injected through intra-
cerebroventricular (ICV) or local cannulae in the brain.
However, there are drawbacks to these techniques. ICV
administration of neuropeptides can be done long term,
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tides remain local with local cannulae, but these experi-
ments are usually short term, because the cannulae can
not be maintained over weeks. To overexpress neuro-
peptides locally and for long periods of time one can
use viral vectors, such as adeno-associated viral (AAV)
vectors [13-15]. There are two problems with the long
term overexpression of neuropeptide genes. Firstly, the
precursor gene encodes for multiple peptides, which
may serve different functions (see above). Therefore,
overexpression of the precursor gene may show the
effects multiple peptides. The second problem, with
overexpression of neuropeptides via viral vectors, is that
the neuropeptide is potentially released in an area to
which the transduced neuron projects rather than secre-
tion locally at the site of transduction; with AAV
mediated overexpression of neuropeptide Y (NPY) in
the paraventricular nucleus (PVN) [13,16] the release of
NPY may thus not be limited to the PVN. In the
hypothalamus there are many interneurons and local
connections, therefore NPY will probably be secreted
locally. However, even in the absence of staining in the
projection areas one can not exclude that a projection
neuron is releasing the neuropeptide elsewhere.
In order to circumvent that overexpression of a neu-
ropeptide gene generates multiple messages and that the
peptide may be released at distant sites, we developed
an AAV vector based method to overcome these pro-
blems. In short, we fused a signal peptide with HA tag
and furin site to the cDNA of a specific minigene,
namely AgRP83-132 or a-MSH. To prevent trafficking of
the minigene into the regulated secretion pathway we
removed the N-terminal part of AgRP or only used the
MSH sequence and made a construct in which a signal
peptide from the Von Willebrand Factor (VWF) was
used to enter the endoplasmic reticulum [17,18]. A furin
cleavage site was inserted between the signal peptide-
H At a ga n dt h em i n i g e n et or e l e a s et h em i n i g e n ef r o m
the signal peptide. Furin is a ubiquitously expressed PC
which is located in the TGN, in stead of in secretory
vesicles, and cycles back and forth to the plasma mem-
brane [19-21]. We used the cDNA of AgRP83-132 as a
minigene, because this is the main secreted form of
AgRP after processing by PC [22]. AgRP is an inverse
agonist for the MC3R and MC4R and stimulates food
intake and reduces energy expenditure, while a-MSH is
a peptide derived from the POMC gene and is able to
activate the MC3R and MC4R to inhibit food intake and
increase energy expenditure [5,23-26]. AgRP and a-
MSH compete to bind to the MC4R and the balance
between these peptides determines the activity of the
MC4R.
Results
VWF-AgRP83-132 and VWF-aMSH are secreted and
biologically active
To investigate if peptides produced from constructs with
a VWF signal peptide followed by a cleavage site and a
neuropeptide are secreted and are biologically active, we
tested whether the medium of cells transfected with the
VWF-AgRP83-132 constructs was able to antagonize
the MC4R. The ability of the VWF-AgRP83-132 to shift
the NDP-MSH dose reponse curve to the right was
compared to a construct encoding for full length AgRP,
containing the normal AgRP signal peptide. Activation
of MC4R in vitro results in an increase in cyclic adeno-
sine monophosphate (cAMP)[27]. In our assay upregula-
tion of cAMP increased LacZ expression through a
cAMP responsive element.
Addition of NDP-MSH to MC4R and CRE-LacZ
transfected cells resulted in a dose response curve with
an EC50 value of 0.1 nM (1 × 10
-10). Another control
was the addition of forskolin to MC4R_Cre-LacZ trans-
fected cells (Figure 1A). Forskolin directly activates ade-
nylyl cyclase, thereby increasing cAMP (control for
transfection of MC4R and CRE-LacZ). When superna-
tants of GFP transfected cells were added together with
different concentrations of NPD-MSH to MC4R_CRE-
LacZ transfected cells, the dose response curve did not
alter. However, addition of supernatants of flAgRP or
VWF-AgRP83-132 transfected cells shifted the NDP-MSH
dose response curve to the right. The EC50 decreased to
1 . 4a n d0 . 5n M ,r e s p e c t i v e l yw h e n1 0 %o ft h ev o l u m e
added was supernatant (Figure 1B). When 50% of the
volume added to the MC4R_CRE-LacZ cells was super-
natant from flAgRP or VWF-AgRP83-132 the NDP-MSH
dose response curve shifted even further to the right
(Figure 1C). In order to determine the amount of
secreted AgRP protein, supernatants were analyzed on a
spot blot (data not shown). This blot showed that 18.2-
fold less AgRP was secreted from the VWF-AgRP83-132
transfected cells compared to flAgRP transfected cells,
even though the transfection efficiencies were similar.
To check if monomeric VWF-aMSH1 and polymeric
VWF-aMSH4 were able to activate the MC4R, different
dilutions of supernatants from cells transfected with
these constructs were added to MC4R_CRE-LacZ trans-
fected cells. Supernatants of both constructs activated
the MC4R, with the polymeric VWF-aMSH4 being
more potent. The polymeric VWF-aMSH4 reached 50%
of MC4R activation at a dilution of 216 times, while
VWF-aMSH1 already reached 50% activation of MC4-R
after 10.7 times dilution. The supernatant of GFP trans-
fected cells was not able to activate the MC4R (Figure
1D,E).
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neurons
We compared the localization of AgRP in primary cortical
neurons which were infected with AAV-flAgRP or AAV-
VWF-AgRP83-132 to check if AAV-VWF-AgRP83-132
entered the regulated secretion pathway. Three days after
infection the primary cortical neurons were stained for
AgRP. In addition, b-tubulin-III was used to stain the
cytoskeleton of neurons and DAPI to identify the cell
nucleus. Neurons transduced with AAV-flAgRP, which
contained the endogenous signal peptide to target AgRP
into the regulated secretory pathways, showed AgRP
immunostaining in their cell bodies and their branches. In
contrast, AAV-VWF-AgRP83-132 transduced neurons only
showed AgRP immunostaining in the cell bodies and
almost no staining in the branches (Figure 2). We did not
observe GFP signal without GFP immunostaining.
Behavioral effects of AAV-VWF-AgRP83-132
To further prove the functionality of AAV-VWF-
AgRP83-132 , this virus was also injected in the PVN of
rats. One μl containing 1 × 10
9 genomic copies of AAV-
VWF-AgRP83-132 or AAV-GFP (as control) was injected
in the PVN (Figure 3A). In situ hybridization against
GFP showed that the PVN was transduced (unilaterally).
Overexpression of AAV-VWF- AgRP83-132 increased
daily food intake when compared to titer matched
AAV-GFP injected rats (p = 0.049) (Figure 3B). In addi-
tion, the AAV-VWF-AgRP83-132 rats showed a signifi-
cant increase in body weight gain compared to
Figure 1 VWF-proteins are secreted and biologically active. A: Dose-response curve of NDP-MSH and forskolin showing their ability to
stimulate 293T cells transfected with MC4R and cAMP sensitive reporter gene. B: similar as 2A, but in the presence of 10% of conditioned
medium from 293T cells transfected with either AAV-GFP, AAV-flAgRP or AAV-VWF-AgRP83-132 . C: similar as 2B, but with 50% of conditioned
medium. D: dose-response curve of NDP-MSH and forskolin as positive control for MC4R and CRE-LacZ transfection. E: response curve of cells
transfected with MC4R and CRE-LacZ incubated with different dilutions of conditioned medium. Medium was taken from cells transfected with
AAV-GFP, AAV-MSH1 or AAV-MSH4. Graphs represent an average of 4 trials.
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injection (Figure 3C).
Discussion
We here successfully demonstrate a novel approach to
locally overexpress a individual neuropeptide rather than
a whole neuropeptide precursor. This was achieved by
fusing a neuropeptide minigene to the VWF signal pep-
tide in a rAAV vector. We demonstrated that the neuro-
peptide minigene was released from the cell body and
did not enter the regulated secretory pathway in vitro.
In addition, we showed that the delivery of the neuro-
peptide minigene, using AAV, to neurons of the PVN
resulted in an increased food intake and body weight.
AAV-flAgRP 
AAV-VWF-AgRP83-132
A: AgRP A’: III -tub A’’
B: AgRP B’: III -tub B’’
Figure 2 Fluorescent immunostaining showing the localization of flAgRP versus VWF-AgRP83-132 . Primary cortical neurons were infected
with AAV-flAgRP(A) or AAV-VWF-AgRP83-132 (B) at a multiplicity of infection of 10.000. Seventy hours after infection neurons were fixed and
immunostained for AgRP (green) and bIII-tubulin (red). “shows the overlay of green and red signals.
Figure 3 In vivo effects of AAV-VWF_AgRP83-132 on energy balance. In situ hybridization showing unilateral transduction of the PVN by 1 μl,
containing 1 x 10
9 g.c., of AAV-VWF-AgRP83-132 (A). AAV-VWF-AgRP83-132 increased food intake (B) and BW gain (C) compared to AAV-GFP. Data
at 28 days post injection (N = 3).
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locally in the brain was effective.
Previous studies have shown that specific signal pep-
tides could route a protein to the regulated pathway.
Fusion of GFP to NPY or insulin signal sequence was
sufficient to route GFP to regulated secretory granules
and resulted in GFP secretion at axon terminals [28,29].
In addition, other groups have already showed that a
secretory signal peptide can be used to direct constitu-
tive peptide secretion from an AAV vector in the rat
b r a i n[ 3 0 , 3 1 ] .I nt h i ss t u d yw es h o w e dt h a ti ti sa l s o
possible to route peptides into the constitutive secretion
pathway resulting in secretion by the cell body, through
the use of the VWF signal peptide and an AgRP frag-
ment that lacked the N terminal part. We replaced the
endogenous signal peptide, N-terminal part and cleavage
site for a VWF signal peptide and a canonical proteoly-
t i cc l e a v a g es i t ef o rf u r i n .N o r m a l l yt h eV W Fi sp r o -
cessed in endothelial cells, however AAV transduces
mainly neurons. Therefore, after the VWF signal peptide
a furin recognition site (RKRR) was inserted, this to
ensure that the VWF signal peptide was cleaved from
AgRP83-132 in neurons. Probably the removal of the
N-terminal part of the AgRP gene has resulted to
constitutive secretion, since it is suggested that the N-
terminal part of prohormone neuropeptides in involved
in the sorting to the secretory or constitutive pathway.
To obtain long term expression of the neuropeptide
minigenes we embedded these DNA constructs in an
rAAV vector. During our study a paper was published
which described a method to deliver two gene products,
GFP and galanin, from one rAAV vector [32]. They
placed a furin sequence between the two genes and the
first gene was fused to a fibronectin secretory signal
peptide to establish constitutive secretion. This con-
firmed the feasibility of using furin as a cleavage site.
First we investigated if the vectors with the VWF
signal peptide are secreted into the medium and com-
pared this with a vector with its endogenous signal
peptide.
The MC4R_CRE-LacZ assay showed that VWF-
AgRP83-132 and VWF-aMSH1 and VWF-aMSH4 were
secreted by 293T cells into the culture medium. The
secreted peptides were also biologically active since the
medium could, respectively, inhibit or activate the
MC4R. The medium of cells transfected with flAgRP
vector, containing the endogenous AgRP signal peptide,
also inhibited the MC4R. However, the inhibition by
flAgRP was stronger than the inhibition caused by med-
i u mf r o mV W F - A g R P 83-132 transfected cells. After the
MC4R assay we determined the amount of protein
secreted in the medium of the cells. This revealed that
there was 18.2 fold less AgRP immunoreactivity in the
medium of VWF-AgRP83-132 transfected cells than in
t h em e d i u mo ff l A g R P .T h ed i f f e r e n c ei np o t e n c y
between VWF-AgRP83-132 and flAgRP to antagonize
NDP-MSH, 0.5 versus 1.4 nM respectively, is in the
range which we expected, since a study by Creemers et.
al. showed that AgRP83-132 was 6.1 fold more potent
than flAgRP in inhibiting the MC4R [22]. Thus, given
the amount of peptide release (18.2 fold less secretion of
VWF-AgRP83-132 than flAgRP) and potencies (VWF-
AgRP83-132 approximately 3 times less potent than
flAgRP) our results are in agreement with the study by
Creemers et al. that VWF-AgRP83-132 is 6 times more
potent than flAgRP.
Medium from cells transfected with AAV-VWF-
aMSH4 was more potent in activating MC4R_CRE-
LacZ than medium from AAV-VWF-aMSH1 trans-
fected cells. Medium from GFP transfected cells was not
able to stimulate MC4R_CRE-LacZ. These data are in
agreement with previous data [33].
In addition, we compared the localization of flAgRP and
VWF-AgRP83-132 in primary neuronal cultures. These
results showed that flAgRP was expressed in the cell body
and in the projections and that VWF-AgRP83-132 was only
expressed in the cell body and not in the projections.
These results were in agreement with the expectation:
peptides coupled to the VWF signal peptide and lacking
the N-terminal part of AgRP entered the constitutive
secretion pathway and the one coupled to the endogenous
AgRP signal peptide plus N-terminal part entered the
regulated secretion pathway in axons.
A sap r o o fo fp r i n c i p l ew es h o w e dt h a tu n i l a t e r a l
overexpression with the VWF-AgRP83-132 AAV vector in
a target area of AgRP neurons, the PVN, increased food
intake. This showed that the VWF-AgRP83-132 is also
functional in vivo.
Conclusions
This study showed that it is possible to overexpress a
single neuropeptide derived from a large precursor and
establish long term release, local to the transduced area,
through the use of a VWF signal peptide.
Methods
Cell lines and constructs
Human embryonic kidney (HEK) 293T cells were main-
tained at 37°C with 5% CO2 in Dulbecco’sm o d i f i e d
Eagles medium (DMEM) supplemented with 10% fetal
calf serum (FCS), 2 mM glutamine, 100 units/ml peni-
cillin, 100 units/ml streptomycin and non-essential
amino acids.
pAAV-GFP with AAV2 inverted terminal resolutions
sites, was previously described [34] and was a kind
gift from M. Sena-Esteves. pAAV-flAgRP-ires-GFP
(Figure 4) was constructed by cloning the full length
mouse Agouti-related protein (AgRP) cDNA in pIRES2-
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isolated and ligated in pAAV-GFP, after removing GFP
from the AAV plasmid. AgeI-furin-AgRP83-132 -EcoRI
was made by PCR on AgRP-ires-GFP with the following
primers: Agrp83f: 5′ gatccaaccggtcgcaagcgtcgttctccgcgt
cgctgtgtaa and ires reverse long: 5′ cggcttcggccagtaacgt-
taggggggggggagggaga. The PCR fragment was subse-
quently digested with AgeI and EcoRI and ligated into
AgeI- EcoRI digested pCMV-VWF-aMSH4-ires-GFP
resulting in pCMV-VWF-AgRP83-132 -ires-GFP.
pCMV-VWF-aMSH1-ires-GFP and pCMV-VWF-
aMSH4-ires-GFP were described elsewhere [33]. The
three pCMV-VWF-neuropeptide-ires-GFP vectors were
digested with AfeI-BsrGI and the VWF-neuropeptide-
ires-GFP parts were isolated and inserted in pAAV-GFP,
resulting in pAAV-VWF-AgRP83-132,p A A V - V W F -
aMSH1 and pAAV-VWF-aMSH4 (Figure 4). Sequences
were verified by sequence analysis.
Figure 4 Vectors used in the study.
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tors has been described [35] and was obtained from
Plasmid factory (Bielefield, Germany).
LacZ reporter gene assay
Activation of the MC4R was determined using LacZ as a
reporter gene [36]. DNA was transfected into cells with
polyethylenimine [37]. Fifty nanograms of human MC4R
and 10 μg of cAMP-responsive element (CRE)-LacZ
were transfected into 293T cells on 10cm dishes.
Another five 10cm dishes with 293T cells were trans-
fected with 10 μg of respectively pAAV-GFP, pAAV-
flAgRP, pAAV-VWF-AgRP83-132 ,p A A V - V W F - aMSH1
and pAAV-VWF-aMSH4. One day after transfection
the MC4R_CRE-LacZ cells were transferred to poly-L-
lysine coated 96-wells plates. Three days after transfec-
t i o ns u p e r n a t a n to f1 0 c md i s h e sw a sr e m o v e da n du s e d
for LacZ reporter assay. At this day the medium was
removed from MC4R_CRE_LacZ transfected cells and
replaced with assay buffer (DMEM containing 0.2%
BSA, 25 mM hepes and 30 μg/ml aprotinin) supplemen-
ted with NDP-MSH alone or in combination with con-
ditioned supernatants of cells transfected with flAgRP,
VWF-AgRP83-132 or GFP. In addition only forskolin was
added to other wells as a positive control for CRE-LacZ
transfection and the subsequent colometric reaction.
The medium of another plate with MC4R_CRE-LacZ
transfected cells was replaced with assay buffer contain-
ing serial dilutions of conditioned medium from cells
transfected with aMSH1, aMSH4 or GFP. As assay con-
trols only NDP-MSH or forskolin were added to other
wells of this plate. After 5-6 hour incubation at 37°C the
assay medium was removed and replaced by 40 μl lysis-
buffer (phosphate buffered saline (PBS) containing 0.1%
Triton-X-100). The plates were stored at -20°C. After
thawing of the plates, 80 μl of substrate (0.1 M phos-
phate buffer, pH7.4, containing 1.6 g/l o-nitrophenyl b-
D-galactopyranoside (ONPG, Invitrogen, the Nether-
lands), 67.5 mM b-mercaptoethanol (Merck, Germany)
and 1.5 mM magnesium chloride) was added to each
well. Absorbance at 405 nm was measured in a Victor
2
microplate reader (PerkinElmer, Brussels, Belgium).
Spot blot
To determine the amount of protein secreted into the
medium of 293T cells transfected with flAgRP, VWF-
AgRP83-132 and GFP a spot blot was performed. A serial
dilution of the medium was made in water. The first
dilution was 20 times followed by 5 times dilutions.
Subsequently 1 μl of undiluted and diluted conditioned
medium was spotted on Hybond-C extra. The blot was
dried and blocked for 10 minutes in PBS containing
0.05% Tween-20 (PBS-T) and 5% milk. Afterwards the
blot was incubated with a rabbit-AgRP antibody
(1:1.000; a kind gift of G. Barsh) in PBS-T for 90 min-
utes, washed three times 10 minutes with PBS-T and
incubated for 60 minutes with goat-anti-rabbit horse-
radish peroxidase (1:20.000) in PBS-T. After three
washes with PBS-T and one wash with PBS the spots
were developed with SuperSignal West Dura extended
duration substrate (Thermo scientific) and exposed to a
CL-film.
AAV production
Each AAV production was performed with 15 dishes of
80-90% confluent 293T cells at day of transfection. Two
hours before transfection, the 10% FCS-DMEM was
replaced with 2% FCS-DMEM. The transfections were
performed with polyethylenimine (PEI) as described by
Reed S.E. et al. [37]. The pAAV plasmids were co-trans-
fected helper plasmid pDp1 in a molar ratio of 1:1. The
transfection mix remained on the cells until the next
day, then the 2% FCS-DMEM was refreshed. The purifi-
cation was performed as described by Zolotukhin et al.
[38]. The titer, in genomic copies per ml (g.c./ml), was
determined by qPCR with sybergreen mix in a LightCyl-
cer (Roche) [39]. The qPCR primers were designed to
detect BGHpolyA and were BGHpolyA_F: 5′ CCT
CGACTGTGCCTTCTAG; BGHpolyA_R: 5′ CCCCA-
GAATAGAATGACACCTA. The titers were AAV-GFPl
1×1 0
13 g.c./ml; AAV-flAgRP 1.7 × 10
14 g.c./ml AAV-
VWF-AgRP83-132 3×1 0
12 g.c./ml; AAV-aMSH4 2.7 ×
10
14 g.c./ml. To obtain titer matched AAV preps, preps
were diluted in PBS.
Animals
All experimental procedures were approved by the
Committee for Animal Experimentation of the Univer-
sity of Utrecht (Utrecht, The Netherlands).
C57BL/6 mice were obtained from Charles River.
Timed-pregnant mice were killed by means of cervical
dislocation. The morning on which a vaginal plug was
detected was considered embryonic day 0.5 (E0.5).
Male Wistar rats, weight ranging from 220-250 g, were
purchased from Charles River. All rats were individually
housed in filtertop cages with ad libitum access to food
(CRM pellets; Special Diet Services, Whitham, Essex, UK)
and water. Animals were kept in a temperature- and
humidity-controlled room (21 ± 2°C) with a 12 h light/
dark cycle (lights on at 7:00 A.M.).
Primary cortical neuron cultures
Cerebral cortices of E16.5 mouse embryos were dis-
sected and dissociated by incubation with 0.25% trypsin
at 37°C for 10-15 minutes, followed by tissue trituration
with a fire-polished pasteurs pipet in DMEM containing
10% FCS and 20 μg/ml DNAseI. After dissociation, the
medium was removed and cells were resuspended in
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ciated cells were plated at a density of 12.000 cells per
well on poly-D-Lysin- (100 μg / m l ;S i g m a ,Z w i j n d r e c h t ,
The Netherlands) and laminin- (40 μg/ml; Invitrogen,
Breda, The Netherlands) coated glass coverslips in 24
well plates. Neuronal cultures were maintained in a
humidified incubator at 37°C and 5% CO2 .A f t e rt w o
days in culture, half of the medium was replaced with
fresh maintenance medium (Neurobasal medium with
B27). Two hours later neurons were infected with the
different AAV vectors at multiplicity of infection 10.000
(thus 1.2 × 10
8 g.c. of AAV vector added per well).
Seventy-two hours after infection neurons were washed
twice with PBS, fixed with 4% paraformaldehyde for 30
minutes and stored in PBS at 4°C.
Immunohistochemistry
Fixed neurons were washed twice with PBS. After
30 minutes incubation in block-t (PBS containing 1%
FCS and 0.1% Triton-X-100) neurons were incubated
overnight with block-t containing rabbit anti-AgRP anti-
body (1:1000, a kind gift from G. Barsh) and mouse
anti-bIII-tubulin (1:3000, Sigm a )a t4 ° C .T h en e x td a y
neurons were washed 3 times with PBS-t (PBS contain-
ing 0.1% Triton-X-100) and incubated for 60 minutes
with secondary antibodies (goat-anti-mouse alexa555
(1:500) and goat-anti-rabbit alexa488 (1:500) (Invitrogen)
in block buffer (PBS containing 1% FCS). Afterwards
neurons were washed 3 times with PBS, incubated with
DAPI (1:3000, Sigma) for 5 minutes, washed 3 times
with PBS and mounted in 90% glycerol in PBS.
In vivo AAV injections
Six rats were anesthetized with fentanyl/fluanisone
(Hypnorm, Janssen Pharmaceutica, Beerse, Belgium,
0.1 ml/100 g intramuscular). Carprofen (Rimadyl®, Pfizer
Animal Health, Capelle a/d Ijssel, The Netherlands, 0.01
ml/100 g subcutaneous) was administered as pain medi-
cation, before surgery and for 2 days after. Subsequently,
the rats were injected unilaterally in the paraventricular
nucleus (PVN, coordinates AP -1.80, ML +1.70, DV -
8.10, angle 10 degrees) with 1 μl of AAV-GFP or AAV-
VWF-AgRP83-132 . The injected volume contained
1x1 0
9 g.c. of AAV vector and was delivered at a rate
of 0.2 μl/minute. Subsequently the injection the needle
remained in the injection site for 10 minutes. Four
weeks after injection the rats were decapitated, the
brains were removed, quickly frozen on dry-ice and
stored at -80°C until they were sectioned on a cryostat
(Leica, The Netherlands) at 20 μm, in series of 10. Serie
1 was used for in situ hybridization with GFP-dig
labeled mRNA probe to show the transduction area of
the AAV vectors and serie 2 for a Nissl staining to show
the overall morphology. The body weight and food
intake data of animals with correct injection sites, as
determined with GFP ISH, were used for behavioral
analysis.
In situ hybridization
In situ hybridization was performed with a 720 basepair
long digoxigenin (DIG)-labeled eGFP riboprobe (anti-
sense to NCBI gene DQ768212) as described by Schae-
ren-Wiemers and Gerfin-Moser [40] with small
modifications in the fixation procedure and hybridiza-
tion temperature. Sections were fixed in 4% PFA for
20 minutes and hybridization was performed at 72°C.
After DIG in situ hybridization, slides were counter-
stained with 0.5% methyl green, quickly dehydrated in
ethanol, cleared in xylene and mounted using Entellan.
Data analysis
Data were analyzed with GraphPad Prism (GraphPad
Software Inc., California). Competition curves were
fitted from duplicate data points using sigmoidal dose
response curve with variable slope.
Body weight gain and food intake were tested with
two sided t-test.
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